Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maxime Dougados

Showing results (471-480 of 600) with videos related to

Pageof 60
Sort By:
The Journal of Rheumatology|March 17, 2010
Reproducibility of joint swelling assessment by sonography in patients with long-lasting rheumatoid arthritis (SEA-Repro study part II)Sandrine Jousse-Joulin, Maria Antonietta d'Agostino, Thierry Marhadour, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|February 15, 2022
Characterization of Blood Mucosal-Associated Invariant T Cells in Patients With Axial Spondyloarthritis and of Resident Mucosal-Associated Invariant T Cells From the Axial Entheses of Non-Axial Spondyloarthritis Control PatientsNicolas Rosine, Hannah Rowe, Surya Koturan, et al.
Annals of the Rheumatic Diseases|March 17, 2017
Safety of synthetic and biological DMARDs: a systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritisSofia Ramiro, Alexandre Sepriano, Katerina Chatzidionysiou, et al.
Joint Bone Spine|April 22, 2006
Nonpharmacological treatments in early rheumatoid arthritis: clinical practice guidelines based on published evidence and expert opinionLaure Gossec, Stephan Pavy, Thao Pham, et al.
Arthritis and Rheumatism|September 2, 2006
Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeksStanley B Cohen, Paul Emery, Maria W Greenwald, et al.
Joint Bone Spine|April 22, 2006
Methotrexate therapy for rheumatoid arthritis: clinical practice guidelines based on published evidence and expert opinionStephan Pavy, Arnaud Constantin, Thao Pham, et al.
Advances in Therapy|October 9, 2020
Real-World Evidence to Contextualize Clinical Trial Results and Inform Regulatory Decisions: Tofacitinib Modified-Release Once-Daily vs Immediate-Release Twice-Daily for Rheumatoid ArthritisStanley B Cohen, Jeffrey D Greenberg, James Harnett, et al.
Annals of the Rheumatic Diseases|December 16, 2006
Clinical trial of a leucotriene B4 receptor antagonist, BIIL 284, in patients with rheumatoid arthritisFederico Díaz-González, Rieke H E Alten, William G Bensen, et al.
Annals of the Rheumatic Diseases|August 14, 2015
Clinical and MRI responses to etanercept in early non-radiographic axial spondyloarthritis: 48-week results from the EMBARK studyWalter P Maksymowych, Maxime Dougados, Désirée van der Heijde, et al.
Lancet (London, England)|October 27, 2018
Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trialDésirée van der Heijde, James Cheng-Chung Wei, Maxime Dougados, et al.
Pageof 60

Showing results (471-480 of 600) with videos related to

Sort By:
Pageof 60
The Journal of Rheumatology|March 17, 2010
Reproducibility of joint swelling assessment by sonography in patients with long-lasting rheumatoid arthritis (SEA-Repro study part II)Sandrine Jousse-Joulin, Maria Antonietta d'Agostino, Thierry Marhadour, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|February 15, 2022
Characterization of Blood Mucosal-Associated Invariant T Cells in Patients With Axial Spondyloarthritis and of Resident Mucosal-Associated Invariant T Cells From the Axial Entheses of Non-Axial Spondyloarthritis Control PatientsNicolas Rosine, Hannah Rowe, Surya Koturan, et al.
Annals of the Rheumatic Diseases|March 17, 2017
Safety of synthetic and biological DMARDs: a systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritisSofia Ramiro, Alexandre Sepriano, Katerina Chatzidionysiou, et al.
Joint Bone Spine|April 22, 2006
Nonpharmacological treatments in early rheumatoid arthritis: clinical practice guidelines based on published evidence and expert opinionLaure Gossec, Stephan Pavy, Thao Pham, et al.
Arthritis and Rheumatism|September 2, 2006
Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeksStanley B Cohen, Paul Emery, Maria W Greenwald, et al.
Joint Bone Spine|April 22, 2006
Methotrexate therapy for rheumatoid arthritis: clinical practice guidelines based on published evidence and expert opinionStephan Pavy, Arnaud Constantin, Thao Pham, et al.
Advances in Therapy|October 9, 2020
Real-World Evidence to Contextualize Clinical Trial Results and Inform Regulatory Decisions: Tofacitinib Modified-Release Once-Daily vs Immediate-Release Twice-Daily for Rheumatoid ArthritisStanley B Cohen, Jeffrey D Greenberg, James Harnett, et al.
Annals of the Rheumatic Diseases|December 16, 2006
Clinical trial of a leucotriene B4 receptor antagonist, BIIL 284, in patients with rheumatoid arthritisFederico Díaz-González, Rieke H E Alten, William G Bensen, et al.
Annals of the Rheumatic Diseases|August 14, 2015
Clinical and MRI responses to etanercept in early non-radiographic axial spondyloarthritis: 48-week results from the EMBARK studyWalter P Maksymowych, Maxime Dougados, Désirée van der Heijde, et al.
Lancet (London, England)|October 27, 2018
Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trialDésirée van der Heijde, James Cheng-Chung Wei, Maxime Dougados, et al.
Pageof 60